CN115105524A - Application of alpha-cyclodextrin in preparing functional food or health product and medicine for improving and protecting pancreatic islet function - Google Patents
Application of alpha-cyclodextrin in preparing functional food or health product and medicine for improving and protecting pancreatic islet function Download PDFInfo
- Publication number
- CN115105524A CN115105524A CN202110288404.5A CN202110288404A CN115105524A CN 115105524 A CN115105524 A CN 115105524A CN 202110288404 A CN202110288404 A CN 202110288404A CN 115105524 A CN115105524 A CN 115105524A
- Authority
- CN
- China
- Prior art keywords
- cyclodextrin
- alpha
- improving
- mice
- functional food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 title claims abstract description 39
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 title claims abstract description 38
- 229940043377 alpha-cyclodextrin Drugs 0.000 title claims abstract description 38
- 210000004153 islets of langerhan Anatomy 0.000 title claims abstract description 21
- 235000013376 functional food Nutrition 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 230000036541 health Effects 0.000 title claims abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 26
- 239000008103 glucose Substances 0.000 claims abstract description 25
- 239000008280 blood Substances 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 30
- 235000009200 high fat diet Nutrition 0.000 abstract description 18
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 230000001771 impaired effect Effects 0.000 abstract description 4
- 208000002705 Glucose Intolerance Diseases 0.000 abstract description 3
- 208000008589 Obesity Diseases 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 235000020824 obesity Nutrition 0.000 abstract description 3
- 201000009104 prediabetes syndrome Diseases 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 2
- 238000004393 prognosis Methods 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 230000003914 insulin secretion Effects 0.000 description 6
- 230000010412 perfusion Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- 238000013218 HFD mouse model Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000277 pancreatic duct Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920005565 cyclic polymer Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of application of alpha-cyclodextrin. The invention discloses an application of alpha-cyclodextrin in preparing functional food or health care products and medicines for improving and protecting pancreatic islet functions. The invention induces the glucose tolerance of mice to be seriously damaged through high fat diet, and improves the severely damaged glucose tolerance to a certain extent through the prognosis of alpha-cyclodextrin. Further research shows that the mice in the high-fat diet group have obvious phenomenon of impaired islet function, and the mice in the group intervened by alpha-cyclodextrin have obvious improvement on the islet function. The research of the invention finds that the alpha-cyclodextrin intervention can achieve the effect of improving impaired glucose tolerance by protecting and improving the functions of the pancreatic islets of mice with obesity and diabetes caused by high fat diet.
Description
Technical Field
The invention belongs to the technical field of application of alpha-cyclodextrin, and particularly relates to application of alpha-cyclodextrin in preparation of functional food or health-care products and medicines for improving and protecting functions of pancreatic islets.
Background
The pancreatic islets are endocrine tissues dispersed in the pancreas, mainly consist of beta-cells secreting insulin and alpha-cells secreting glucagon, and play a key role in regulating the blood glucose homeostasis of a human body. Normal human blood glucose can be maintained at a relatively stable level during fasting and postprandial periods as a result of co-regulation by the body's glycemic hormone (glucagon) and hypoglycemic hormone (insulin). Insulin is the most important blood sugar-reducing hormone in the body, and the secretion quantity, the secretion time and the functional condition of the insulin directly determine the level of blood sugar, so that the change of the function of the pancreatic islets has an important determining function on the onset, the condition and the severity of diabetes.
Alpha-cyclodextrin (alpha-CD) is a cyclic polymer consisting of 6 glucose units with polar hydroxyl groups facing outward. The core of the ring is hydrophobic and readily binds to a variety of hydrophobic compounds, including free fatty acids. The U.S. department of agriculture recognizes the safety of alpha-CD to humans from an official perspective based on extensive clinical laboratory data. α -CD has excellent physicochemical properties and can be used in a variety of fields. The application fields which are relatively mature and widely accepted at present comprise the fields of using the dietary fiber as soluble dietary fiber or improving the material of metabolic syndrome in functional foods, pharmaceutical excipients and the like.
At present, the application and research of alpha-cyclodextrin in improving and protecting pancreatic islet function are not available in the published literature.
Disclosure of Invention
The invention aims to solve the problems and provides a technical scheme for improving the prior art, and provides application of alpha-cyclodextrin in preparing functional foods or health-care products and medicines for improving and protecting islet functions. The invention utilizes high-fat feed to feed C57BL/6 mice for 18 weeks, simulates the onset process of obesity and diabetes of human bodies, and simultaneously uses alpha-cyclodextrin to intervene for 18 weeks, thereby researching the influence of the alpha-cyclodextrin on the islet function of the mice with high-fat diet.
The purpose of the invention and the technical problem to be solved are realized by adopting the following technical scheme.
The invention provides application of alpha-cyclodextrin in preparing functional food or health-care product for improving and protecting pancreatic islet function.
Preferably, the functional food or health care product is a functional food or health care product for improving the function of pancreatic islets and reducing the blood sugar concentration.
Preferably, the addition amount of the alpha-cyclodextrin in the functional food or the health-care product is 0.5-30%.
Preferably, the functional food or health product is in the form of any one of suspension, granule, capsule, powder, tablet, emulsion and solution.
The purpose of the invention and the technical problem to be solved are realized by adopting the following technical scheme.
The invention provides an application of alpha-cyclodextrin in preparing a medicament for improving and protecting functions of pancreatic islets.
Preferably, the medicament is a medicament for improving pancreatic islet function and reducing blood glucose concentration.
Preferably, the addition amount of the alpha-cyclodextrin in the medicament is 0.5-30%.
Preferably, the dosage form of the medicament is an oral preparation.
Preferably, the oral preparation is a tablet, a pill, a granule, an oral liquid or a capsule.
In conclusion, the invention has the following beneficial effects: the invention induces the glucose tolerance of mice to be seriously damaged through high fat diet, and improves the severely damaged glucose tolerance to a certain extent through the prognosis of alpha-cyclodextrin. Further research shows that mice in the high-fat diet group have obvious phenomenon of impaired islet function, and the islet function of the mice in the group intervened by alpha-cyclodextrin is obviously improved. The research of the invention finds that the alpha-cyclodextrin intervention can achieve the effect of improving impaired glucose tolerance by protecting and improving the functions of the pancreatic islets of mice with obesity and diabetes caused by high fat diet.
The foregoing is a summary of the present invention, and in order to provide a clear understanding of the technical means of the present invention and to be implemented in accordance with the present specification, the following is a detailed description of the preferred embodiments of the present invention.
Drawings
The invention is further described below with reference to the accompanying drawings, in which:
fig. 1 is a glucose tolerance test: a blood sugar change curve before and after glucose is injected into the abdominal cavity of the mouse;
FIG. 2 shows insulin secretion from mouse islet cells under different feeding conditions;
FIG. 3 shows insulin secretion from mouse islet cells under different feeding conditions.
In the figure, NF is normal diet group; HF is a high fat diet group; HF + alpha-CD is a group of high fat diet + alpha-cyclodextrin.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is described in further detail below with reference to the accompanying drawings and embodiments. It is to be noted that the drawings are merely illustrative and not to be drawn to strict scale, and that some portions may be enlarged or reduced for convenience of description, and some default may be made for a known portion.
Example 1 Experimental preparation
The experimental mice selected in the embodiment are 5-week-old male C57BL/6 mice purchased from Nanjing Jiejiekang Biotech limited, and the production license number of the experimental animal is SCXK (Su) 2018-0008.
The model feed code TP23400 used in the experiments was provided by Nantong Telofurant feed science and technology, Inc. Wherein, the energy supply ratio of the high-fat feed is as follows: fat 60%, carbohydrate 25.9%, protein 14.1%; energy supply ratio of common feed: 10% of fat, 75.9% of carbohydrate and 14.1% of protein.
The specific method comprises the following steps: feeding mice in cages of 3-4 mice per cage, wherein the ventilation condition in an animal house is good, the light changes normally day and night (8:00 am-8: 00pm), the relative humidity is kept at 40-70%, the room temperature is 23 +/-2 ℃, and after adaptive feeding is carried out for 1 week, the mice are randomly divided into 3 groups as follows: (1) normal diet group (normal feed, NF, n ═ 12); (2) high fat diet group (high fat diet, HF, n ═ 12); (3) high fat diet + α -cyclodextrin group (high fat diet, 5% α -cyclodextrin added to drinking water, HF + α -CD, n ═ 12). The experiment was carried out continuously for 18 weeks. All mice were free to eat and drink water during the experiment.
Example 2 glucose tolerance test
Three groups of mice were raised to 18 weeks, fasted overnight for 12 hours, and glucose was administered by intraperitoneal injection at a dose of 11.1ul per gram of body weight (2g/kg body weight), and blood glucose was measured by tail apex blood at 0, 30min, 60min, 90min, 120min, and 150min after injection. The results are shown in FIG. 1.
Example 3 islet perfusion experiment
Firstly, islet separation, purification and culture:
mice were anesthetized with teletamine hydrochloride and bled, then sacrificed, mice were fixed to plates, the abdominal cavity opened, the pancreas exposed, the pancreatic duct closed with hemostats into the entrance to the duodenum, and then 2mg/ml collagenase (type V) was injected into the pancreatic duct, dissolved in Hanks buffer. The pancreas was then peeled off, placed in a 50ml centrifuge tube, and 5ml collagenase (2mg/ml) was added and shaken manually for 5 minutes in a water bath at 37 ℃. Then 40ml Hanks buffer was added, centrifuged, the supernatant discarded, the pellet resuspended and plated on a plate, islets were manually picked under a dissecting microscope, and then cultured in RPMI1640 medium (10mM glucose, 10% FBS, 2mM glutamine, antibiotic 1%, pH7.4) overnight. Mouse islets were each isolated and purified separately.
II, islet perfusion experiment:
glucose stimulated insulin secretion (glucose concentration from 0 to 25mM, concentration gradient ramp, increase 0.5mM per minute), Krebs-Ringer biocarbonate Buffer (KRBB) (115mmol/L NaCl,24mmol/L NaHCO3,5mmol/L KCl,1mmol/L MgCl2,2.5mmol/L CaCl2,10mM HEPES, pH7.4) plus 0.25% BSA, perfusion flow 1 mL/min. 120 islets were manually picked up, placed in an perfusion device, perfused with a Waters 600HPLC pump, while one sample per minute was collected with a sample collector, and finally the islets were stimulated with 30mM KCl. The insulin detection kit of Cisbio was used for the insulin determination of the samples. The results are shown in FIGS. 2 and 3.
Example 4 results and analysis
1. Alpha-cyclodextrin intervention improves glucose tolerance in high-fat diet mice:
first, the basal blood glucose values in overnight fasting mice showed that fasting blood glucose (15mmol/L) was significantly higher in high-fat diet mice than in normal diet mice (7.8mmol/L), and that alpha-cyclodextrin intervention had no significant effect on fasting blood glucose. After 30min of intraperitoneal glucose injection to overnight fasting mice, the blood glucose of the HF group mice rapidly increased and was significantly higher than that of the NF group in the same period (p < 0.01). Then, the blood sugar of the NF mice gradually decreases, the blood sugar of the HF mice is maintained at a high level for 30-90 min, and the blood sugar slowly decreases after 120min and 150min, which indicates that the glucose tolerance of the mice is seriously impaired due to high-fat diet. The α -Cyclodextrin intervention pre-group (HF + α -CD) mice exhibited a 90min drop in blood glucose and were significantly lower than the HF control at 120min and 150min (see FIG. 1). Experiments prove that long-term high-fat diet can simulate the progress of human diabetes, mice have obvious abnormal sugar tolerance, and the intervention of alpha-cyclodextrin can improve the severely damaged sugar tolerance to a certain extent.
2. The intervention of alpha-cyclodextrin can obviously improve the function of pancreatic islet:
after 18 weeks of experiment, the islet of the mouse is separated, and after overnight culture, the insulin secretion stimulated by glucose is evaluated by an islet perfusion experiment, and the result shows that the islet cells of the high-fat diet diabetic mouse have the insulin secretion amount of only about half of that of NF group mice after glucose stimulation (see figure 2), and the phenomenon that the function of the islet of the high-fat diet mouse is obviously damaged is suggested. The islet function of mice in the alpha-cyclodextrin intervention group is obviously improved (see figure 3), and is basically consistent with the improvement of glucose tolerance in a living body experiment, so that the abnormal glucose tolerance of the mice with high fat diet is related to the impaired function of insulin secretion of the islets, and the long-time alpha-cyclodextrin intervention can improve the islet function and improve the glucose tolerance.
In a word, the intervention of the alpha-cyclodextrin can achieve the effect of improving impaired glucose tolerance by protecting and improving the pancreatic islet function of obese and diabetic mice caused by high-fat diet.
The above-mentioned embodiments, which further illustrate the objects, technical solutions and advantages of the present invention, should be understood that the above-mentioned embodiments are only exemplary of the present invention, and not restrictive, and any simple modifications, equivalent changes and modifications made to the above-mentioned embodiments according to the technical spirit of the present invention are within the scope of the technical solutions of the present invention.
Claims (9)
1. Application of alpha-cyclodextrin in preparing functional food or health product for improving and protecting pancreatic islet function.
2. The use according to claim 1, wherein the functional food or health product is a functional food or health product for improving pancreatic islet function and reducing blood glucose concentration.
3. The use according to claim 1, wherein the amount of the alpha-cyclodextrin added to the functional food or health product is 0.5-30%.
4. The use according to claim 1, wherein the functional food or health care product is in the form of any one of suspension, granule, capsule, powder, tablet, emulsion and solution.
5. The application of alpha-cyclodextrin in preparing medicine for improving and protecting pancreatic island function.
6. The use of claim 5, wherein the medicament is a medicament for improving pancreatic islet function and lowering blood glucose concentration.
7. The use of claim 5, wherein the amount of α -cyclodextrin added to the medicament is 0.5 to 30%.
8. The use of claim 5, wherein the medicament is in a dosage form for oral administration.
9. The use according to claim 8, wherein the oral formulation is a tablet, pill, granule, oral liquid or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110288404.5A CN115105524A (en) | 2021-03-18 | 2021-03-18 | Application of alpha-cyclodextrin in preparing functional food or health product and medicine for improving and protecting pancreatic islet function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110288404.5A CN115105524A (en) | 2021-03-18 | 2021-03-18 | Application of alpha-cyclodextrin in preparing functional food or health product and medicine for improving and protecting pancreatic islet function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115105524A true CN115105524A (en) | 2022-09-27 |
Family
ID=83324314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110288404.5A Pending CN115105524A (en) | 2021-03-18 | 2021-03-18 | Application of alpha-cyclodextrin in preparing functional food or health product and medicine for improving and protecting pancreatic islet function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115105524A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1447014A1 (en) * | 2003-02-14 | 2004-08-18 | Wacker-Chemie GmbH | Method for reducing the glycemic index for food |
| CN105031619A (en) * | 2015-08-13 | 2015-11-11 | 上海交通大学医学院附属瑞金医院 | Application of excreted factor GREM2 to 2-type diabetic therapy drug preparation |
| CN112472723A (en) * | 2020-12-14 | 2021-03-12 | 烟台大学 | A product containing sea squirt inner bag and its preparation method |
-
2021
- 2021-03-18 CN CN202110288404.5A patent/CN115105524A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1447014A1 (en) * | 2003-02-14 | 2004-08-18 | Wacker-Chemie GmbH | Method for reducing the glycemic index for food |
| CN105031619A (en) * | 2015-08-13 | 2015-11-11 | 上海交通大学医学院附属瑞金医院 | Application of excreted factor GREM2 to 2-type diabetic therapy drug preparation |
| CN112472723A (en) * | 2020-12-14 | 2021-03-12 | 烟台大学 | A product containing sea squirt inner bag and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108125937A (en) | Purposes of the spermidine in prevention and treatment fatty liver and diabetes B | |
| CN114259507B (en) | Application of klebsiella minutissima in preparing medicine for treating and/or preventing hyperuricemia related diseases | |
| CN101584704B (en) | Medicinal application of medicinal salt or derivative of heparin and low molecular heparin | |
| CN108003199B (en) | Enteromorpha oligosaccharide with blood sugar reducing function and preparation method and application thereof | |
| CN101703497B (en) | Application of Chlorogenic acid in preparing drug having protection and restoration functions on spleen hematopoietic stem cell injuries | |
| CN115105524A (en) | Application of alpha-cyclodextrin in preparing functional food or health product and medicine for improving and protecting pancreatic islet function | |
| CN101444599B (en) | Corn silk extract and preparation method thereof and application thereof in preparing drugs for treating gout | |
| CN101212963B (en) | The use of chlorogenic acid in the manufacture of medicaments for increasing the effect of bone marrow cells | |
| CN109419787B (en) | Application of abietane diterpenoid compound | |
| CN110432492A (en) | A kind of hypoglycemic nano-clathrate and preparation method thereof | |
| CN105012826A (en) | Alpinia oxyphylla leaf extract and preparation method and application thereof | |
| CN101695485B (en) | Use of chlorogenic acid in preparing medicament for treating thrombocytopenia and anemia | |
| CN107158026A (en) | Application of the low-ester pectin in preventing and treating or auxiliary treatment diabetes | |
| CN108219024B (en) | Calophyllum inophyllum flower polysaccharide, extraction method thereof and application thereof in preparing medicine for treating functional constipation | |
| CN110585308A (en) | Golden camellia three-leaf tea and preparation method and application thereof | |
| CN111265627B (en) | Sea cucumber polysaccharide composition for regulating intestinal flora and preparation method and application thereof | |
| CN116270634B (en) | Application of Zhongwuning in preparing medicine for preventing and treating liver diseases | |
| CN107462683B (en) | Research method for uric acid and blood sugar reducing effect of polygonum cuspidatum | |
| CN101618157B (en) | Medicine composition for treating autumn-dryness cold and preparation method thereof | |
| CN1919277B (en) | Application of pharmaceutical composition in the process for preparing medicine of enhancing insulin sensitivity | |
| CN106913558B (en) | Glucose sustained-release preparation for treating glycogen accumulation disease | |
| CN113057967A (en) | Stem cell composition for treating diabetes and preparation and application thereof | |
| CN101695486B (en) | Use of chlorogenic acid in preparing medicament for treating marrow fibrillation | |
| CN114948890A (en) | Technetium [ alpha ], [ alpha ] 99 Tc]Methylene diphosphonate coated tablet and its preparation method | |
| CN114712481A (en) | Composite plant source polypeptide and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |